Belen Pascual
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Belen Pascual has a total of 476 co-authors. Here are the top co-authors by number of shared publications:
- Joseph C. Masdeu
Nantz National Alzheimer Center, Houston Methodist Neurological Institute and Weill Cornell Medicine, Houston, TX 77030, USA
19 shared publications John Kornak
Department of Neurology, Edward and Pearl Fein Memory and Aging Center University of California, San Francisco San Francisco CA
9 shared publicationsKatya Rascovsky
8 shared publications- Nupur Ghoshal
Departments of Neurology and Psychiatry, Washington University School of Medicine, Washington University, St. Louis, USA
8 shared publications - Bradley F. Boeve
Mayo Clinic Rochester
7 shared publications Walter Kremers
Department of Quantitative Health Sciences, Mayo Clinic Rochester MN
7 shared publications
Latest Publications
- Open Access
Detection of tau spatial extent using MK6240 and flortaucipir PET
INTRODUCTION: Tau PET enables in vivo quantification of neurofibrillary tangle spread, yet whether tau spatial extent (TSE) performs comparably across tracers remains unknown. METHODS: We performed a head-to-head comparison of Flortaucipir and MK6240 tau PET in 682 individuals across the AD continuum, quantifying TSE as the percentage of regional voxels exceeding a tracer-specific abnormality threshold and evaluated it as a metric of tracer comparability. RESULTS: MK6240 showed greater TSE than Flortaucipir (CU Aβ+, medial temporal lobe [MTL]: 42% vs 25%; dementia Aβ+, late neocortical: 55% vs 42%), reaching 50% detection probability at lower Aβ burden (Centiloid: MTL, 26 vs 45; late neocortical, 95 vs 118). TSE showed higher associations than SUVR with memory, Aβ PET, and plasma pTau217, particularly in the neo-late composite. Participants with intermediate tau involvement (TSE 25–50%), most below the SUVR positivity thresholds (MTL positivity 10.2–16.9%), had approximately three-fold higher odds of Aβ PET and pTau217 positivity than TSE 0–25% (ORs 2.90–3.46). 53.4% of intermediate Flortaucipir cases (TSE 25–50%) shifted to a higher MK6240 category, and 82.5% of moderately high Flortaucipir cases (50–75%) were classified as near-saturated (75–100%) by MK6240. Neither raw TSE nor raw SUVR was directly interchangeable across tracers, with systematic and proportional bias for both metrics (MTL Deming slope: TSE 1.29; SUVR 2.69). DISCUSSION: TSE showed stronger unadjusted associations than SUVR in selected region- and outcome-specific comparisons, supporting its potential as a complementary measure. Like SUVR, raw TSE values were not directly interchangeable between flortaucipir and MK6240, and tracer-specific calibration and validation are required before cross-tracer use.
Open AccessDetection of tau spatial extent using MK6240 and flortaucipir PET
INTRODUCTION: Tau PET enables in vivo quantification of neurofibrillary tangle spread, yet whether tau spatial extent (TSE) performs comparably across tracers remains unknown. METHODS: We performed a head-to-head comparison of Flortaucipir and MK6240 tau PET in 682 individuals across the AD continuum, quantifying TSE as the percentage of regional voxels exceeding a tracer-specific abnormality threshold and evaluated it as a metric of tracer comparability. RESULTS: MK6240 showed greater TSE than Flortaucipir (CU Aβ+, medial temporal lobe [MTL]: 42% vs 25%; dementia Aβ+, late neocortical: 55% vs 42%), reaching 50% detection probability at lower Aβ burden (Centiloid: MTL, 26 vs 45; late neocortical, 95 vs 118). TSE showed higher associations than SUVR with memory, Aβ PET, and plasma pTau217, particularly in the neo-late composite. Participants with intermediate tau involvement (TSE 25–50%), most below the SUVR positivity thresholds (MTL positivity 10.2–16.9%), had approximately three-fold higher odds of Aβ PET and pTau217 positivity than TSE 0–25% (ORs 2.90–3.46). 53.4% of intermediate Flortaucipir cases (TSE 25–50%) shifted to a higher MK6240 category, and 82.5% of moderately high Flortaucipir cases (50–75%) were classified as near-saturated (75–100%) by MK6240. Neither raw TSE nor raw SUVR was directly interchangeable across tracers, with systematic and proportional bias for both metrics (MTL Deming slope: TSE 1.29; SUVR 2.69). DISCUSSION: TSE showed stronger unadjusted associations than SUVR in selected region- and outcome-specific comparisons, supporting its potential as a complementary measure. Like SUVR, raw TSE values were not directly interchangeable between flortaucipir and MK6240, and tracer-specific calibration and validation are required before cross-tracer use.
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3) , e000142
Associations of Plasma GDF15, CRP, and IL-6 With Cognitive Trajectories in Patients With Frontotemporal Lobar Degeneration
Background and ObjectivesPlasma growth differentiation factor 15 (GDF15), a TGFbeta family cytokine, has been robustly identified from proteomics discovery work as linked to adverse brain aging; im...
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3) , e000142
Open AccessAssociations of Plasma GDF15, CRP, and IL-6 With Cognitive Trajectories in Patients With Frontotemporal Lobar Degeneration
Background and ObjectivesPlasma growth differentiation factor 15 (GDF15), a TGFbeta family cytokine, has been robustly identified from proteomics discovery work as linked to adverse brain aging; im...
- Open Access
- 3 March 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (2)
Peripheral immune profiling in frontotemporal dementia
Frontotemporal dementia (FTD) encompasses a heterogenous and clinically diverse group of disorders, including the behavioural variant frontotemporal dementia, the non-fluent and the semantic variants of primary progressive aphasia. While these subtypes present with distinct clinical features, emerging evidence implicates neuroinflammation as a shared pathogenic mechanism. Nevertheless, little is known regarding the status of the peripheral immune system in the pathogenesis of FTD. Blood samples were obtained from 27 individuals with a clinical diagnosis of FTD (7 behavioural variants FTD, 10 non-fluent and 10 semantic variants of primary progressive aphasia) and 25 age-matched healthy controls. The immunophenotypes of peripheral immune cell populations were assessed with multicolour flow cytometry. Regulatory T cells were isolated and co-cultured with responder T cells and proliferation was determined by 3H-thymidine incorporation. The immune-related transcriptomic profile of isolated monocytes was analysed using the NanoString Human Inflammation Panel. Plasma levels of inflammatory cytokines and chemokines were quantified using the Olink® Target 48 Cytokine panel. Our analysis demonstrated that the suppressive function of regulatory T cells on responder T cells proliferation was significantly compromised in FTD individuals compared to healthy controls (P < 0.05). Transcriptomic profiling of FTD monocytes revealed a potential dysregulation of 153 immune-related genes. Enrichment analysis showed that these genes were mainly involved in chemokine-mediated signalling pathway, monocyte and lymphocyte chemotaxis, response to interferon-gamma and positive regulation of ERK1 and ERK2 cascades. Proteomic analysis of plasma inflammatory mediators showed a significant increase in the pro-inflammatory cytokine TNFa (P < 0.05) and the chemokines CXCL10, CCL3, CCL19, CSF1 (P < 0.05) and CXCL12 (P < 0.01) in FTD individuals compared to healthy controls. These findings provide the first evidence that the immunomodulatory function of regulatory T cells is compromised in individuals with FTD. In addition, there is a dysregulation of inflammation-related gene expression in peripheral monocytes and an increase of plasma inflammatory chemokines and cytokines in FTD individuals. Further investigation is warranted to assess the therapeutic potential of restoring dysfunctional regulatory T cells and modulating the inflammatory profile in the clinical setting of FTD.
- 3 March 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (2)
Open AccessPeripheral immune profiling in frontotemporal dementia
Frontotemporal dementia (FTD) encompasses a heterogenous and clinically diverse group of disorders, including the behavioural variant frontotemporal dementia, the non-fluent and the semantic variants of primary progressive aphasia. While these subtypes present with distinct clinical features, emerging evidence implicates neuroinflammation as a shared pathogenic mechanism. Nevertheless, little is known regarding the status of the peripheral immune system in the pathogenesis of FTD. Blood samples were obtained from 27 individuals with a clinical diagnosis of FTD (7 behavioural variants FTD, 10 non-fluent and 10 semantic variants of primary progressive aphasia) and 25 age-matched healthy controls. The immunophenotypes of peripheral immune cell populations were assessed with multicolour flow cytometry. Regulatory T cells were isolated and co-cultured with responder T cells and proliferation was determined by 3H-thymidine incorporation. The immune-related transcriptomic profile of isolated monocytes was analysed using the NanoString Human Inflammation Panel. Plasma levels of inflammatory cytokines and chemokines were quantified using the Olink® Target 48 Cytokine panel. Our analysis demonstrated that the suppressive function of regulatory T cells on responder T cells proliferation was significantly compromised in FTD individuals compared to healthy controls (P < 0.05). Transcriptomic profiling of FTD monocytes revealed a potential dysregulation of 153 immune-related genes. Enrichment analysis showed that these genes were mainly involved in chemokine-mediated signalling pathway, monocyte and lymphocyte chemotaxis, response to interferon-gamma and positive regulation of ERK1 and ERK2 cascades. Proteomic analysis of plasma inflammatory mediators showed a significant increase in the pro-inflammatory cytokine TNFa (P < 0.05) and the chemokines CXCL10, CCL3, CCL19, CSF1 (P < 0.05) and CXCL12 (P < 0.01) in FTD individuals compared to healthy controls. These findings provide the first evidence that the immunomodulatory function of regulatory T cells is compromised in individuals with FTD. In addition, there is a dysregulation of inflammation-related gene expression in peripheral monocytes and an increase of plasma inflammatory chemokines and cytokines in FTD individuals. Further investigation is warranted to assess the therapeutic potential of restoring dysfunctional regulatory T cells and modulating the inflammatory profile in the clinical setting of FTD.
- Open Access
- 29 January 2026
- Published by Wiley in Annals of Neurology
- Vol. 99 (5) , 1315-1326
Individualized Atrophy‐Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed‐Effects Modeling
Objective: Age of symptom onset is highly variable in familial frontotemporal lobar degeneration (f‐FTLD). Accurate prediction of onset would inform clinical management and trial enrollment. Prior studies indicate that individualized maps of brain atrophy can predict conversion to dementia in f‐FTLD. We used a Bayesian linear mixed‐effect (BLME) prediction method for identifying accelerated brain volume loss to predict conversion to dementia. Methods: Participants included 234 asymptomatic or prodromal carriers of C9orf72 , GRN , or MAPT mutations (including 21 dementia converters) with ≥3 longitudinal magnetic resonance imaging (MRI) T1‐weighted scans. The BLME models established individual voxel‐wise gray matter trajectories using the first 2 scans. Person‐specific clusters of accelerated volume loss were estimated in subsequent scans and tested as predictors of dementia conversion compared with other approaches in time‐varying Cox proportional hazard models covarying for age. Receiver‐operating characteristic (ROC) curves estimated utility of cluster volume in discriminating which participants converted to dementia within 24 months. Results: The BLME cluster volume predicted conversion to dementia in f‐FTLD mutation carriers overall and separately in C9orf72 , GRN , and MAPT , with comparable hazard ratios observed for atrophy W‐maps and regional volumes. Within a 24‐month timeframe, BLME cluster volume discriminated dementia converters from non‐converters with larger areas under the curve (AUCs) than other approaches. Interpretation: Bayesian‐modeled individualized atrophy scores predict dementia progression among asymptomatic f‐FTLD mutation carriers and may have increased utility compared with other structural imaging methods when studying individuals over shorter timeframes that align with clinical trial design. ANN NEUROL 20269999:n/a–n/a
- 29 January 2026
- Published by Wiley in Annals of Neurology
- Vol. 99 (5) , 1315-1326
Open AccessIndividualized Atrophy‐Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed‐Effects Modeling
Objective: Age of symptom onset is highly variable in familial frontotemporal lobar degeneration (f‐FTLD). Accurate prediction of onset would inform clinical management and trial enrollment. Prior studies indicate that individualized maps of brain atrophy can predict conversion to dementia in f‐FTLD. We used a Bayesian linear mixed‐effect (BLME) prediction method for identifying accelerated brain volume loss to predict conversion to dementia. Methods: Participants included 234 asymptomatic or prodromal carriers of C9orf72 , GRN , or MAPT mutations (including 21 dementia converters) with ≥3 longitudinal magnetic resonance imaging (MRI) T1‐weighted scans. The BLME models established individual voxel‐wise gray matter trajectories using the first 2 scans. Person‐specific clusters of accelerated volume loss were estimated in subsequent scans and tested as predictors of dementia conversion compared with other approaches in time‐varying Cox proportional hazard models covarying for age. Receiver‐operating characteristic (ROC) curves estimated utility of cluster volume in discriminating which participants converted to dementia within 24 months. Results: The BLME cluster volume predicted conversion to dementia in f‐FTLD mutation carriers overall and separately in C9orf72 , GRN , and MAPT , with comparable hazard ratios observed for atrophy W‐maps and regional volumes. Within a 24‐month timeframe, BLME cluster volume discriminated dementia converters from non‐converters with larger areas under the curve (AUCs) than other approaches. Interpretation: Bayesian‐modeled individualized atrophy scores predict dementia progression among asymptomatic f‐FTLD mutation carriers and may have increased utility compared with other structural imaging methods when studying individuals over shorter timeframes that align with clinical trial design. ANN NEUROL 20269999:n/a–n/a
- Open Access
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S2) , e103463
Inflammation clinical trial in mild to moderate Alzheimer's disease: TSPO‐PET results
Background: Brain inflammation can be assessed using translocator protein (TSPO) PET because TSPO is highly expressed by microglia, peripherally‐derived macrophages, and astrocytes. However, TSPO PET cannot differentiate between M1 (neurotoxic) and M2 (neuroprotective) microglial phenotypes. The utility of TSPO PET in tracking brain inflammation during Alzheimer's disease (AD) clinical trials targeting inflammation remains largely unexplored. To address this gap, we report on a TSPO‐PET study performed before and after an immunomodulation clinical trial for AD. TSPO‐PET was performed using 11 C‐ER176, a tracer with high specific binding, a favorable metabolite profile, and increased uptake in AD, particularly in brain regions with elevated tau levels. Method: Thirty‐eight AD patients (ages 50‐86, MMSE scores 12‐26) participated in a phase 2a, randomized, double‐blind, placebo‐controlled trial evaluating two dosing frequencies of Interleukin‐2 (IL‐2). Over a 21‐week period, 9 participants received IL‐2 every 4 weeks (IL‐2 q4wks), 10 received IL‐2 every 2 weeks (IL‐2 q2wks), and 19 received placebo. 11 C‐ER176 PET (using standard methods and an arterial‐input function), blood/CSF biomarkers, and clinical scores were obtained before and after treatment. Result: Group analyses revealed no differences in TSPO‐PET binding before and after the IL‐2 dosing regimens or placebo. Both IL‐2 regimens significantly increased Treg numbers and function, with IL‐2 q4wks being more effective in enhancing Treg counts and Foxp3 mean fluorescence intensity. In the IL‐2 q4wks group, CSF Aβ42 levels improved significantly ( p = 0.045), with a strong trend toward stabilized CSF NfL levels ( p = 0.061). CSF GFAP levels remained stable with both IL‐2 q4wks and IL‐2 q2wks regimens but increased substantially in the placebo group. No significant changes were observed in CSF p ‐Tau181 levels across all groups. Notably, IL‐2 q4wks regimen was associated with a slowing of cognitive decline compared to placebo, highlighting their potential therapeutic benefit in this context. Conclusion: While IL‐2 immunotherapy every 4 weeks enhanced Treg populations, showing promising trends in AD biomarkers and clinical scales, TSPO‐PET was largely unchanged over the 21 weeks of the trial. A longer follow‐up period, a larger sample size, or, more likely, PET tracers specific for M1 and M2 macrophages or other inflammation targets are needed for future clinical trials.
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S2) , e103463
Open AccessInflammation clinical trial in mild to moderate Alzheimer's disease: TSPO‐PET results
Background: Brain inflammation can be assessed using translocator protein (TSPO) PET because TSPO is highly expressed by microglia, peripherally‐derived macrophages, and astrocytes. However, TSPO PET cannot differentiate between M1 (neurotoxic) and M2 (neuroprotective) microglial phenotypes. The utility of TSPO PET in tracking brain inflammation during Alzheimer's disease (AD) clinical trials targeting inflammation remains largely unexplored. To address this gap, we report on a TSPO‐PET study performed before and after an immunomodulation clinical trial for AD. TSPO‐PET was performed using 11 C‐ER176, a tracer with high specific binding, a favorable metabolite profile, and increased uptake in AD, particularly in brain regions with elevated tau levels. Method: Thirty‐eight AD patients (ages 50‐86, MMSE scores 12‐26) participated in a phase 2a, randomized, double‐blind, placebo‐controlled trial evaluating two dosing frequencies of Interleukin‐2 (IL‐2). Over a 21‐week period, 9 participants received IL‐2 every 4 weeks (IL‐2 q4wks), 10 received IL‐2 every 2 weeks (IL‐2 q2wks), and 19 received placebo. 11 C‐ER176 PET (using standard methods and an arterial‐input function), blood/CSF biomarkers, and clinical scores were obtained before and after treatment. Result: Group analyses revealed no differences in TSPO‐PET binding before and after the IL‐2 dosing regimens or placebo. Both IL‐2 regimens significantly increased Treg numbers and function, with IL‐2 q4wks being more effective in enhancing Treg counts and Foxp3 mean fluorescence intensity. In the IL‐2 q4wks group, CSF Aβ42 levels improved significantly ( p = 0.045), with a strong trend toward stabilized CSF NfL levels ( p = 0.061). CSF GFAP levels remained stable with both IL‐2 q4wks and IL‐2 q2wks regimens but increased substantially in the placebo group. No significant changes were observed in CSF p ‐Tau181 levels across all groups. Notably, IL‐2 q4wks regimen was associated with a slowing of cognitive decline compared to placebo, highlighting their potential therapeutic benefit in this context. Conclusion: While IL‐2 immunotherapy every 4 weeks enhanced Treg populations, showing promising trends in AD biomarkers and clinical scales, TSPO‐PET was largely unchanged over the 21 weeks of the trial. A longer follow‐up period, a larger sample size, or, more likely, PET tracers specific for M1 and M2 macrophages or other inflammation targets are needed for future clinical trials.
- 19 November 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 47 (5) , 1315-1319
β-Amyloid PET Signal Reduction in Prior ARIA-E Regions after Antiamyloid Therapy for Alzheimer Disease
BACKGROUND AND PURPOSE: The relationship between regional brain edema caused by anti-amyloid monoclonal antibodies (ARIA-E) and the degree of regional β-amyloid (Aβ) positron emission tomography (PET) signal reduction is unknown. MATERIALS AND METHODS: In patients with moderate or severe ARIA-E, we quantified changes in Aβ PET signal before and after ARIA-E resolution, comparing regions affected by ARIA-E with unaffected regions. RESULTS: In four of five patients treated with lecanemab or donanemab and who had moderate or severe ARIA-E, Aβ PET signal decreased significantly more in regions that had been involved with ARIA-E. CONCLUSIONS: Greater regional Aβ PET signal reduction in areas affected by ARIA-E may reflect enhanced local Aβ clearance, reduced tracer binding site availability, impaired glymphatic flow from immune complex deposition, or other mechanisms. The finding of greater regional Aβ PET signal reduction in ARIA-E regions refines the characterization of ARIA-E and raises the possibility that its occurrence may have beneficial as well as adverse implications. ABBREVIATIONS: ARIA= amyloid related imaging abnormalities; Aβ= β-amyloid; SUVR = standard uptake value ratio
- 19 November 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 47 (5) , 1315-1319
β-Amyloid PET Signal Reduction in Prior ARIA-E Regions after Antiamyloid Therapy for Alzheimer Disease
BACKGROUND AND PURPOSE: The relationship between regional brain edema caused by anti-amyloid monoclonal antibodies (ARIA-E) and the degree of regional β-amyloid (Aβ) positron emission tomography (PET) signal reduction is unknown. MATERIALS AND METHODS: In patients with moderate or severe ARIA-E, we quantified changes in Aβ PET signal before and after ARIA-E resolution, comparing regions affected by ARIA-E with unaffected regions. RESULTS: In four of five patients treated with lecanemab or donanemab and who had moderate or severe ARIA-E, Aβ PET signal decreased significantly more in regions that had been involved with ARIA-E. CONCLUSIONS: Greater regional Aβ PET signal reduction in areas affected by ARIA-E may reflect enhanced local Aβ clearance, reduced tracer binding site availability, impaired glymphatic flow from immune complex deposition, or other mechanisms. The finding of greater regional Aβ PET signal reduction in ARIA-E regions refines the characterization of ARIA-E and raises the possibility that its occurrence may have beneficial as well as adverse implications. ABBREVIATIONS: ARIA= amyloid related imaging abnormalities; Aβ= β-amyloid; SUVR = standard uptake value ratio
- 30 July 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (1) , 505-517
Translocator protein (TSPO) positron emission tomography imaging and expression in patients with brain metastases
Purpose 18 kDa translocator protein (TSPO) is a biomarker for inflammatory conditions. However, full kinetic positron emission tomography (PET) modeling has rarely been used to quantify brain tumors, and it has never been used in brain metastases (BMs). This proof-of-principle study quantified TSPO expression using full kinetic modeling in patients with BMs from various types of peripheral primary tumors. Methods Nine adult patients with BMs and 12 healthy volunteers (HVs) took part in the study. The total distribution volume (VT) of 11C-ER176 was calculated with a two-tissue compartment model (2TCM) and metabolite-corrected arterial input function in the BMs and in the rest of the brain. Immunohistochemistry (IHC) and single-cell RNAseq database were used to quantify TSPO expression in vitro. The VT values of the hemisphere contralateral to the BMs were compared to the cortical values of HVs. Results 11C-ER176 uptake was increased in BMs compared with the rest of the brain of each participant. The BM time-activity curves were well-fitted by the 2TCM, and the resulting VT (range 3.2–13 mL/cm3) was identified with precision (standard error generally < 5%). The rate constant mostly affected by the integrity of the blood–brain barrier (BBB) (K1) was similar between the BMs and the contralateral hemisphere. TSPO expression was detected by IHC in tumor regions and variably in microglia/macrophages, a finding largely corroborated by single-cell RNAseq database. The average VT of the rest of the brain in BM patients was significantly lower than in HVs, which may have been due to immunosuppressive therapy. Conclusion In this pilot study, full kinetic modeling quantified TSPO expression in BMs with good fit and precision. The kinetic modeling outcome parameters and the TSPO expression levels in vitro suggest that 11C-ER176 binding was largely specific and not significantly affected by disruption of the BBB.
- 30 July 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (1) , 505-517
Translocator protein (TSPO) positron emission tomography imaging and expression in patients with brain metastases
Purpose 18 kDa translocator protein (TSPO) is a biomarker for inflammatory conditions. However, full kinetic positron emission tomography (PET) modeling has rarely been used to quantify brain tumors, and it has never been used in brain metastases (BMs). This proof-of-principle study quantified TSPO expression using full kinetic modeling in patients with BMs from various types of peripheral primary tumors. Methods Nine adult patients with BMs and 12 healthy volunteers (HVs) took part in the study. The total distribution volume (VT) of 11C-ER176 was calculated with a two-tissue compartment model (2TCM) and metabolite-corrected arterial input function in the BMs and in the rest of the brain. Immunohistochemistry (IHC) and single-cell RNAseq database were used to quantify TSPO expression in vitro. The VT values of the hemisphere contralateral to the BMs were compared to the cortical values of HVs. Results 11C-ER176 uptake was increased in BMs compared with the rest of the brain of each participant. The BM time-activity curves were well-fitted by the 2TCM, and the resulting VT (range 3.2–13 mL/cm3) was identified with precision (standard error generally < 5%). The rate constant mostly affected by the integrity of the blood–brain barrier (BBB) (K1) was similar between the BMs and the contralateral hemisphere. TSPO expression was detected by IHC in tumor regions and variably in microglia/macrophages, a finding largely corroborated by single-cell RNAseq database. The average VT of the rest of the brain in BM patients was significantly lower than in HVs, which may have been due to immunosuppressive therapy. Conclusion In this pilot study, full kinetic modeling quantified TSPO expression in BMs with good fit and precision. The kinetic modeling outcome parameters and the TSPO expression levels in vitro suggest that 11C-ER176 binding was largely specific and not significantly affected by disruption of the BBB.
- Open Access
- 7 July 2025
- Published by Springer Nature in Nature Aging
- Vol. 5 (7) , 1372
Author Correction: Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
- 7 July 2025
- Published by Springer Nature in Nature Aging
- Vol. 5 (7) , 1372
Open AccessAuthor Correction: Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
- 4 July 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (1) , 418-428
TSPO circadian pattern: a test-retest study of [11C]ER176
- 4 July 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (1) , 418-428
TSPO circadian pattern: a test-retest study of [11C]ER176
- Open Access
- 16 May 2025
- Published by Springer Nature in Nature Aging
- Vol. 5 (6) , 1143-1158
Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
The pathophysiological mechanisms driving disease progression of frontotemporal lobar degeneration (FTLD) and corresponding biomarkers are not fully understood. Here we leveraged aptamer-based proteomics (>4,000 proteins) to identify dysregulated communities of co-expressed cerebrospinal fluid proteins in 116 adults carrying autosomal dominant FTLD mutations (C9orf72, GRN and MAPT) compared with 39 non-carrier controls. Network analysis identified 31 protein co-expression modules. Proteomic signatures of genetic FTLD clinical severity included increased abundance of RNA splicing (particularly in C9orf72 and GRN) and extracellular matrix (particularly in MAPT) modules, as well as decreased abundance of synaptic/neuronal and autophagy modules. The generalizability of genetic FTLD proteomic signatures was tested and confirmed in independent cohorts of (1) sporadic progressive supranuclear palsy-Richardson syndrome and (2) frontotemporal dementia spectrum clinical syndromes. Network-based proteomics hold promise for identifying replicable molecular pathways in adults living with FTLD. ‘Hub’ proteins driving co-expression of affected modules warrant further attention as candidate biomarkers and therapeutic targets.
- 16 May 2025
- Published by Springer Nature in Nature Aging
- Vol. 5 (6) , 1143-1158
Open AccessLarge-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
The pathophysiological mechanisms driving disease progression of frontotemporal lobar degeneration (FTLD) and corresponding biomarkers are not fully understood. Here we leveraged aptamer-based proteomics (>4,000 proteins) to identify dysregulated communities of co-expressed cerebrospinal fluid proteins in 116 adults carrying autosomal dominant FTLD mutations (C9orf72, GRN and MAPT) compared with 39 non-carrier controls. Network analysis identified 31 protein co-expression modules. Proteomic signatures of genetic FTLD clinical severity included increased abundance of RNA splicing (particularly in C9orf72 and GRN) and extracellular matrix (particularly in MAPT) modules, as well as decreased abundance of synaptic/neuronal and autophagy modules. The generalizability of genetic FTLD proteomic signatures was tested and confirmed in independent cohorts of (1) sporadic progressive supranuclear palsy-Richardson syndrome and (2) frontotemporal dementia spectrum clinical syndromes. Network-based proteomics hold promise for identifying replicable molecular pathways in adults living with FTLD. ‘Hub’ proteins driving co-expression of affected modules warrant further attention as candidate biomarkers and therapeutic targets.